Responses
Clinical/translational cancer immunotherapy
Original research
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Compose a Response to This Article
Other responses
No responses have been published for this article.